Sign In
Buy BMRN
$56.47
+1.81 (+3.31%)
At Close: Jun 04, 2026
Drug/Biotech Stocks' Apr 27 Q1 Earnings Roster: GSK, AMGN & More
03:44pm, Tuesday, 26'th Apr 2022 Zacks Investment Research
Let us take a look at four drug/biotech companies, namely, GSK, AMGN, ALKS and BMRN, which are due to release their quarterly results on Apr 27.
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
02:07pm, Monday, 25'th Apr 2022 Benzinga
Upgrades
RBC Capital upgraded the previous rating for United States Steel Corp (NYSE:X) from Sector Perform to Outperform. United States Steel earned $3.64 in the fourth quarter, compared to $0.27 in
10 Biggest Price Target Changes For Monday
11:53am, Monday, 25'th Apr 2022 Benzinga
Keybanc cut Salesforce, Inc. (NYSE: CRM) price target from $281 to $223. Salesforce shares fell 1.1% to $169.60 in pre-market trading.
Raymond James cut the price target for Avery Dennison Corporat
7 Potential Biotech Stocks Buyout Targets in 2022
08:10am, Thursday, 21'st Apr 2022
Big biopharma companies usually rely on M&A to get immediate access to a new class of drug or technology, fill in the gap in their pipeline and compensate for revenue loss from patent expiration of bl
Why Is BioMarin (BMRN) Up 4.6% Since Last Earnings Report?
03:30pm, Friday, 25'th Mar 2022 Zacks Investment Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is BioMarin (BMRN) Up 4.6% Since Last Earnings Report?
01:33pm, Friday, 25'th Mar 2022
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
Sanofi's (SNY) Hemophilia A Candidate Meets Study Endpoints
03:26pm, Thursday, 10'th Mar 2022 Zacks Investment Research
Sanofi (SNY) and Sobi's factor VIII replacement therapy candidate, efanesoctocog alfa, achieves clinically meaningful prevention of bleeds in people with severe hemophilia A
BioMarin: Keep Waiting For The Growth
04:43pm, Thursday, 03'rd Mar 2022
BioMarin released positive financials, but investors were disappointed by some clinical trial data.
Why BioMarin Pharmaceutical Tumbled on Thursday
10:09pm, Thursday, 24'th Feb 2022 The Motley Fool
While the company broadly met expectations for the fourth quarter, investors seemed concerned about its 2022 guidance.
Why BioMarin Pharmaceutical Tumbled on Thursday
10:09pm, Thursday, 24'th Feb 2022 The Motley Fool
While the company broadly met expectations for the fourth quarter, investors seemed concerned about its 2022 guidance.
Why BioMarin Pharmaceutical Tumbled on Thursday
05:09pm, Thursday, 24'th Feb 2022
While the company broadly met expectations for the fourth quarter, investors seemed concerned about its 2022 guidance.
BioMarin (BMRN) Q4 Earnings Top Estimates, Sales Fall Y/Y
03:50pm, Thursday, 24'th Feb 2022 Zacks Investment Research
Biomarin Pharmaceutical's (BMRN) fourth-quarter earnings and sales beat estimates. Stock declines
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
01:01pm, Thursday, 24'th Feb 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Adagio Appoints COO David Hering As Interim CEO
Adagio Therapeutics, Inc., (NASDAQ: ADGI) announced th
BioMarin (BMRN) Q4 Earnings Top Estimates, Sales Fall Y/Y
12:20pm, Thursday, 24'th Feb 2022
Biomarin Pharmaceutical's (BMRN) fourth-quarter earnings and sales beat estimates. Stock declines
